Identifying Therapeutic Targets for CNS Inflammation
Author Information
Author(s): Arsalan S. Haqqani, Danica B. Stanimirovic
Primary Institution: Institute for Biological Sciences, National Research Council, Ottawa, ON, Canada
Hypothesis
Using advanced methods that combine membrane and submembrane proteomics and glycoproteomics with methods of in silico interactomics, a novel set of intercellular interactions between human brain endothelial cells and human CNS-homing T cells, can be identified and exploited as therapeutic targets for preventing brain inflammation caused by recruitment of peripheral inflammatory cells.
Conclusion
The study successfully demonstrates that novel interacting molecules between CNS-homing T cells and activated brain endothelial cells can be discovered, which may serve as therapeutic targets for inhibiting CNS inflammation.
Supporting Evidence
- Leukocyte infiltration across an activated brain endothelium contributes to neuroinflammation in neurological disorders.
- IL-17-producing T-lymphocytes have brain-homing capabilities and contribute to multiple sclerosis and cerebral ischemia.
- Blocking antibodies against specific intercellular interacting pairs have shown promise in preclinical studies.
Takeaway
Scientists are trying to find new ways to stop inflammation in the brain by looking for special proteins that help immune cells get into the brain. These proteins could be used to create new medicines.
Methodology
The study used advanced membrane and submembrane proteomic methods combined with in silico interactomics to identify intercellular interactions between brain endothelial cells and Th17 lymphocytes.
Limitations
The study primarily focuses on a limited number of known molecules and may overlook other potential targets due to the complexity of interactions.
Participant Demographics
The study involved lymphocytes isolated from multiple sclerosis patients.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website